Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - A phase II study

Oncology

Volumn 73, Issue 1-2, 2008, Pages 21-25

  Hau, P ^c   Kunz Schughart, L ^a   Bogdahn, U ^c   Baumgart, U ^c   Hirschmann, B ^c   Weimann, E ^b   Muhleisen H ^b   Ruemmele, P ^c   Steinbrecher, A ^c   Reichle, A ^c  

^a OncoRay   (Germany)

^b KLINIKUM LUDWIGSBURG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Anaplastic glioma; Capecitabine; Drug resistance; Glioblastoma; Low dose chemotherapy; Pioglitazone; Rofecoxib; Temozolomide

Indexed keywords

CAPECITABINE; CD31 ANTIGEN; CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROFECOXIB; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DACARBAZINE; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; EDEMA; EFFERENT PATHWAYS; ERYTHEMA; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LACTONES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; SULFONES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 41549147888     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000120028     Document Type: Article

References (19)

1. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-2578.
2. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
3. Hahnfeldt P, Folkman J, Hlatky L: Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003;220:545-554.
4. Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, Krause SW, Andreesen R: Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004;101:2247-2256.
5. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS: Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103:329-338.
6. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C: Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet 2000;37:410-414.
7. Strakova N, Ehrmann J, Bartos J, Malikova J, Dolezel J, Kolar Z: Peroxisome proliferator-activated receptor (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 2005;52:126-136
8. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61:4375-4381.
9. Jantke J, Ladehoff M, Kurzel F, Zapf S, Kim E, Giese A: Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir (Wien) 2004;146:483-494.
10. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2004;131:31-40.
11. Reichle A, Vogt T, Coras B, Bross K, Terheyden P, Neuber K, Trefzer U, Schultz E, Fischer von Weikersthal L, Andreesen R: Metronomic chemotherapy plus/minus antiinflammatory treatment in far advanced melanoma: a randomized multi-institutional phase II trial (abstract 3139). ASCO 2005;23:165.
12. Reichle A, Grassinger J, Bross K, Wilke J, Suedhoff T, Walter B, Wieland WF, Berand A, Andreesen R: C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomarker Insights 2006;2:87-98.
13. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
15. Stadlmann S, Gueth U, Wight E, Kunz-Schughart L, Hartmann A, Singer G: Expression of peroxisome proliferator activated receptor-gamma and cyclooxygenase-2 in primary and recurrent ovarian carcinoma. J Clin Pathol 2007;60:307-310.
16. Cimini A, Cristiano L, Colafarina S, Benedetti E, Di Loreto S, Festuccia C, Amicarelli F, Canuto RA, Ceru MP: PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int J Cancer 2005;117:923-933.
17. Hara A, Okayasu I: Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol (Berlin) 2004;108:43-48.
18. Sminia P, Stoter TR, van der Valk P, Elkhuizen PH, Tadema TM, Kuipers GK, Vandertop WP, Lafleur MV, Slotman BJ: Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:653-661.
19. Michael MS, Badr MZ, Badawi AF: Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med 2003;11:733-736.